Please assess the completion status of the following clinical trial:

Trial Title: Maintenance Dovitinib for Colorectal and Pancreas Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a confirmed diagnosis of:~  1. Stage 4 colon cancer either s/p metastasectomy or post-initial chemotherapy or maintenance standard of care, either involving 5-fluorouracil/leucovorin (5-FU/LV) alone or continual bevacizumab alone. Patients in maintenance cohort must have had 2 consecutive CT scans showing stable disease and not be experiencing significant prior treatment-related toxicity above Grade 1.~ 2. Pancreas cancer, either s/p resection and adjuvant chemotherapy or locally advanced pancreas cancer s/p chemotherapy and radiation. Initial chemotherapy or radiation therapy may have been stopped between 2 weeks and 2 months prior to study start, and patients must have recovered from prior treatment related toxicity to grade 1 or less.~* Prior surgery, including tumor resection or metastasectomy must have been performed at least 4 weeks prior to study enrollment.~* No concomitant anti-cancer treatment is allowed~* Age \>/= 18 years~* Performance status of 0-1~* Adequate hepatic, bone marrow, and renal function~* Partial thromboplastin time (PTT) must be \</= 1.5 x upper normal limit of institution's normal range and INR (International Normalized Ratio) \< 1.5.~* Life expectancy \>/= 4 months for maintenance cohorts and \>/= 6 months for adjuvant cohorts~* Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and must not be lactating.~* Subject is capable of understanding and complying with protocol demands and able to sign and date the informed consent~Exclusion Criteria:~* Women of child-bearing potential, who are biologically able to conceive, not employing two forms of highly effective contraception or who are pregnant.~* Women who are breast-feeding~* Fertile males unwilling to use contraception~* Patients with brain metastases or any history of brain metastases~* Patients who have undergone major surgery (e.g., intra-thoracic, -abdominal, or -pelvic) \</= 4 weeks prior to starting study treatment or who have not recovered from such therapy~* Patients with a history of pulmonary embolism, or untreated deep vein thrombosis within the past 6 months~* Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of dovitinib~* The subject has had another active malignancy within the past 5 years except for cervical cancer in situ, in situ carcinoma of the bladder or non-melanoma carcinoma of the skin.~* Patients who have received the last administration of an anticancer therapy including chemotherapy, immunotherapy, hormonal therapy and monoclonal antibodies \</= 2 weeks prior to starting the study drug, or who have not recovered from the side effects of such therapy~* Cirrhosis, chronic active hepatitis or chronic persistent hepatitis~* Patients who are currently receiving prasugrel~* No concurrent use of isoniazid, labetolol, trovafloxacin, tolcapone, and felbamate~* No concurrent use of other investigational drugs or antineoplastic therapies.~* Patients with impaired cardiac function or clinically significant cardiac diseases.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dovitinib (Type: EXPERIMENTAL): Dovitinib 500 mg orally daily for 5 days followed by 2 days off (7 day cycles) for up to 2 years

Based on this trial design, predict the completion outcome and termination type (if applicable).